VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Norovirus Infection
Conditions
Norovirus Infection
Trial Timeline
Mar 20, 2019 → Apr 1, 2021
NCT ID
NCT03897309About VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets
VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets is a phase 1 stage product being developed by Vaxart for Norovirus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03897309. Target conditions include Norovirus Infection.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07254728 | Phase 1 | Completed |
| NCT03897309 | Phase 1 | Completed |
Competing Products
11 competing products in Norovirus Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine Tablet | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-T | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN | Vaxart | Phase 1/2 | 33 |
| VXA-G1.1-NN Oral Vaccine | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN | Vaxart | Phase 1 | 25 |
| Norwalk GI.1 Virus | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum | Vaxart | Phase 1/2 | 33 |
| Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + Placebo | Vaxart | Phase 2 | 44 |
| VXA-GI.1.NN + Placebo Tablet | Vaxart | Phase 1 | 25 |
| CDI-988 + Placebo | Cocrystal Pharma | Phase 1/2 | 33 |